The NICHD Contraception Research Branch (CRB) is conducting research related to developing contraceptives technologies with anti-infective properties against pathogens such as HIV, Bacterial Vaginosis, Chlamydia, etc. – Multipurpose Prevention Technologies. This contract is to support facilitating coordination between relevant stakeholders in multipurpose prevention technology (MPT) development, including product developers, funding agencies, regulatory bodies, academic researchers, the media, and the public in a product neutral capacity to aid in the development of novel MPTs. Note: MPTs are products containing multiple preventative functions, most commonly they consist of a contraceptive plus an HIV preventative but can contain other anti-infectives as long as the product has at least two indications. • Knowledge maintenance - Compile and host resources relevant to MPTs including but not limited to: a. An up-to-date database of all MPTs currently under development. b. Current funding opportunities announcements relevant to MPT developers from NIH and other national and international funders. c. Recent news and publications in the field. d. Relevant webinars, lectures, etc. e. Resources for trainees interested in a career in MPT research. f. Resources for product developers on how best to include underrepresented constituencies in MPT research. g. Any other relevant resources that would be of use to stakeholders in MPT development. • Collaboration and information sharing - Maintain and grow a contact list of stakeholders in MPT development including people from government, academia, industry, philanthropy, and funding agencies. - Provide monthly updates to these stakeholders of relevant news, information, publications, etc. relevant to the MPT field. - Organize and host quarterly events (seminar, panel discussion, lecture, etc.) on a topic relevant to stakeholders. One of the four topics must be specifically related to Diversity, Equity, Inclusion, and Accessibility (DEIA) relevant to MPT stakeholders. Topics could include but would not be limited to: a. Addressing vaginal health in MPT development. b. Incorporating end-user input into MPT product development. c. Transitioning a product from pre-clinical to clinical development. d. Regulatory considerations for MPT products. - Act as a communication hub for current and future stakeholders by: a. Facilitating introductions and interactions between current MPT stakeholders, particularly across disciplines. b. Participating in outreach to potential stakeholders (traveling to and presenting posters or talks at relevant meetings, engaging with potential funders about MPTs) • Ongoing assessment of the MPT development field. - At least 1 publication assessing various gaps and barriers in MPT development, including strategies to overcome these issues. Topics could include but would not be limited to: a. DEIA issues relevant to MPT development. b. Encouraging investment from biote...